Trade Sino Biopharmaceutical Limited - 1177 CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.12 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025961% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004043% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | HKD | ||||||||
Margin | 5% | ||||||||
Stock exchange | Hong Kong | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Sino Biopharmaceutical Ltd ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 3.44 |
Open* | 3.44 |
1-Year Change* | -21.82% |
Day's Range* | 3.26 - 3.44 |
52 wk Range | 2.57-5.00 |
Average Volume (10 days) | 86.99M |
Average Volume (3 months) | 1.20B |
Market Cap | 70.88B |
P/E Ratio | 35.59 |
Shares Outstanding | 18.80B |
Revenue | 31.54B |
EPS | 0.11 |
Dividend (Yield %) | 2.12202 |
Beta | 0.71 |
Next Earnings Date | Mar 29, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 7, 2023 | 3.30 | -0.06 | -1.79% | 3.36 | 3.38 | 3.24 |
Dec 6, 2023 | 3.38 | -0.04 | -1.17% | 3.42 | 3.46 | 3.34 |
Dec 5, 2023 | 3.44 | -0.02 | -0.58% | 3.46 | 3.54 | 3.40 |
Dec 4, 2023 | 3.48 | -0.24 | -6.45% | 3.72 | 3.74 | 3.46 |
Dec 1, 2023 | 3.66 | -0.12 | -3.17% | 3.78 | 3.80 | 3.66 |
Nov 30, 2023 | 3.78 | 0.12 | 3.28% | 3.66 | 3.82 | 3.60 |
Nov 29, 2023 | 3.66 | -0.10 | -2.66% | 3.76 | 3.82 | 3.66 |
Nov 28, 2023 | 3.76 | 0.08 | 2.17% | 3.68 | 3.78 | 3.62 |
Nov 27, 2023 | 3.68 | -0.08 | -2.13% | 3.76 | 3.76 | 3.66 |
Nov 24, 2023 | 3.70 | -0.08 | -2.12% | 3.78 | 3.80 | 3.68 |
Nov 23, 2023 | 3.80 | 0.08 | 2.15% | 3.72 | 3.82 | 3.70 |
Nov 22, 2023 | 3.72 | -0.02 | -0.53% | 3.74 | 3.74 | 3.66 |
Nov 21, 2023 | 3.74 | -0.04 | -1.06% | 3.78 | 3.80 | 3.70 |
Nov 20, 2023 | 3.76 | -0.04 | -1.05% | 3.80 | 3.82 | 3.72 |
Nov 17, 2023 | 3.78 | 0.18 | 5.00% | 3.60 | 3.80 | 3.60 |
Nov 16, 2023 | 3.70 | -0.04 | -1.07% | 3.74 | 3.76 | 3.60 |
Nov 15, 2023 | 3.76 | 0.12 | 3.30% | 3.64 | 3.78 | 3.64 |
Nov 14, 2023 | 3.60 | 0.00 | 0.00% | 3.60 | 3.66 | 3.54 |
Nov 13, 2023 | 3.60 | 0.18 | 5.26% | 3.42 | 3.60 | 3.38 |
Nov 10, 2023 | 3.38 | -0.02 | -0.59% | 3.40 | 3.40 | 3.32 |
Sino Biopharmaceutical Limited Events
Time (UTC) | Country | Event |
---|---|---|
Friday, March 29, 2024 | ||
Time (UTC) 10:59 | Country HK
| Event Full Year 2023 Sino Biopharmaceutical Ltd Earnings Release Full Year 2023 Sino Biopharmaceutical Ltd Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 28780.4 | 26861.4 | 23647.2 | 24234 | 20888.6 |
Revenue | 28780.4 | 26861.4 | 23647.2 | 24234 | 20888.6 |
Cost of Revenue, Total | 5795.51 | 5332.1 | 5182.32 | 4926.27 | 4196.93 |
Gross Profit | 22984.9 | 21529.3 | 18464.9 | 19307.8 | 16691.7 |
Total Operating Expense | 22409.8 | 21610.9 | 18307.6 | 18424.9 | 9366.15 |
Selling/General/Admin. Expenses, Total | 12564 | 12763.6 | 11628.6 | 11797 | 10268 |
Interest Expense (Income) - Net Operating | -172.512 | -1110.37 | -963.72 | -561.3 | -568.428 |
Unusual Expense (Income) | 25.527 | 639.276 | -4.58 | -0.903 | -6557.24 |
Other Operating Expenses, Total | -55.912 | 308.971 | -161.711 | -134.863 | -63.724 |
Operating Income | 6370.64 | 5250.5 | 5339.65 | 5809.16 | 11522.4 |
Interest Income (Expense), Net Non-Operating | -592.034 | 13322.2 | -326.601 | -118.565 | -93.354 |
Net Income Before Taxes | 5778.6 | 18572.7 | 5013.04 | 5690.59 | 11429.1 |
Net Income After Taxes | 5002.62 | 16614.8 | 4340.67 | 4787.85 | 10732.8 |
Minority Interest | -2459.05 | -2006.38 | -1569.58 | -2026.3 | -1686.5 |
Net Income Before Extra. Items | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Net Income | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Income Available to Common Excl. Extra. Items | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Income Available to Common Incl. Extra. Items | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Diluted Net Income | 2311.2 | 14125.9 | 2771.09 | 2761.54 | 9046.35 |
Diluted Weighted Average Shares | 19017.2 | 19283 | 18800.3 | 18811.1 | 18548.5 |
Diluted EPS Excluding Extraordinary Items | 0.12153 | 0.73256 | 0.1474 | 0.1468 | 0.48771 |
Dividends per Share - Common Stock Primary Issue | 0.10598 | 0.06519 | 0.06172 | 0.04766 | 0.04292 |
Diluted Normalized EPS | 0.12269 | 0.76241 | 0.14719 | 0.14743 | 0.15597 |
Research & Development | 4253.15 | 3677.26 | 2626.71 | 2398.71 | 2090.57 |
Dilution Adjustment | -232.37 | -482.511 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 15277 | 13586.7 | 15193.7 | 26861.4 | 7110.79 |
Revenue | 15277 | 13586.7 | 15193.7 | 26861.4 | 7110.79 |
Cost of Revenue, Total | 3256.5 | 2835.91 | 2959.6 | 5332.1 | 1337.41 |
Gross Profit | 12020.5 | 10750.8 | 12234.1 | 21529.3 | 5773.38 |
Total Operating Expense | 11529.3 | 10636.8 | 11773 | 21610.9 | 5006.58 |
Selling/General/Admin. Expenses, Total | 6444.36 | 5630.1 | 6933.9 | 12703.6 | 3180.71 |
Research & Development | 2357.26 | 2204.55 | 2048.6 | 3677.26 | 767.055 |
Interest Expense (Income) - Net Operating | -313.83 | 17.194 | -189.706 | -818.075 | -181.424 |
Unusual Expense (Income) | -14.761 | -1.162 | 7.288 | -3.731 | -0.794 |
Other Operating Expenses, Total | -200.24 | -49.832 | 13.321 | 719.681 | -96.374 |
Operating Income | 3747.74 | 2949.91 | 3420.73 | 5250.5 | 2104.21 |
Interest Income (Expense), Net Non-Operating | -523.575 | -925.918 | 333.884 | 13322.2 | 6032.95 |
Net Income Before Taxes | 3224.17 | 2023.99 | 3754.61 | 18572.7 | 8137.16 |
Net Income After Taxes | 2699.42 | 1819.4 | 3183.22 | 16614.8 | 7247.19 |
Minority Interest | -1440.64 | -1196.86 | -1262.18 | -2006.38 | -680.348 |
Net Income Before Extra. Items | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Net Income | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Income Available to Common Excl. Extra. Items | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Income Available to Common Incl. Extra. Items | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Diluted Net Income | 1258.78 | 551.1 | 1760.1 | 14125.9 | 6566.84 |
Diluted Weighted Average Shares | 18564.2 | 18911.7 | 19122.7 | 19283 | 19289.1 |
Diluted EPS Excluding Extraordinary Items | 0.06781 | 0.02914 | 0.09204 | 0.73256 | 0.34044 |
Dividends per Share - Common Stock Primary Issue | 0.01851 | 0.05299 | 0.05122 | 0.03259 | 0.01663 |
Diluted Normalized EPS | 0.06714 | 0.02909 | 0.09237 | 0.73258 | 0.34041 |
Dilution Adjustment | -71.433 | -160.937 | -482.511 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 25934.9 | 23503.2 | 22794.2 | 24913.1 | 18538.1 |
Cash and Short Term Investments | 16921.7 | 15794.1 | 16431.8 | 19105.6 | 13022.7 |
Cash | 6413.98 | 6213.97 | 6596.5 | 4340.18 | 3956.99 |
Cash & Equivalents | 2240.82 | 3385.56 | 4027.69 | 6291.03 | 2278.04 |
Short Term Investments | 8266.86 | 6194.51 | 5807.63 | 8474.34 | 6787.64 |
Total Receivables, Net | 6218.71 | 5537.26 | 4075.75 | 3342.97 | 3865.17 |
Accounts Receivable - Trade, Net | 4638.4 | 4220.67 | 2914.08 | 2712.21 | 2924.04 |
Total Inventory | 2328.84 | 1937.74 | 1880.05 | 1658.6 | 1209.16 |
Prepaid Expenses | 465.687 | 234.127 | 406.578 | 805.972 | 404.009 |
Other Current Assets, Total | 37.116 | ||||
Total Assets | 64064.3 | 60543.3 | 47210.4 | 37514.2 | 49780.2 |
Property/Plant/Equipment, Total - Net | 9251.18 | 8516.06 | 8392.2 | 7633.22 | 5804.37 |
Property/Plant/Equipment, Total - Gross | 13858.3 | 12490.9 | 11475.9 | 10013.8 | 7176.27 |
Accumulated Depreciation, Total | -4607.08 | -3974.82 | -3083.65 | -2380.6 | -1371.91 |
Goodwill, Net | 662.611 | 647.93 | 88.926 | 88.926 | 13897 |
Intangibles, Net | 1251.84 | 1064.02 | 924.71 | 1324.21 | 8349.17 |
Long Term Investments | 25950.3 | 25875.1 | 11215.4 | 2582.92 | 1437.27 |
Other Long Term Assets, Total | 1013.41 | 937.04 | 3795.02 | 971.814 | 1754.29 |
Total Current Liabilities | 20150.7 | 15345 | 10943.5 | 8123.02 | 9668.62 |
Accounts Payable | 1637.35 | 1693.15 | 1947.8 | 1809.44 | 1832.17 |
Accrued Expenses | 6299.15 | 5145.84 | 4190.39 | 3560.56 | 3252.42 |
Notes Payable/Short Term Debt | 136.13 | 136.13 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 9723.84 | 6585.04 | 1581.52 | 689.828 | 2905.57 |
Other Current Liabilities, Total | 2354.2 | 1784.86 | 3223.82 | 2063.19 | 1678.46 |
Total Liabilities | 34317.2 | 30252.2 | 30463.3 | 22564.9 | 20567.4 |
Total Long Term Debt | 4258.12 | 5685.27 | 13067.5 | 7926.07 | 507.066 |
Long Term Debt | 3933.86 | 5365.32 | 12802.6 | 7884.8 | 507.066 |
Deferred Income Tax | 831.791 | 881.59 | 171.652 | 423.261 | 1522.06 |
Minority Interest | 8196.51 | 7437.91 | 5672.4 | 5611.94 | 8336.69 |
Other Liabilities, Total | 880.146 | 902.433 | 608.201 | 480.652 | 532.941 |
Total Equity | 29747 | 30291.1 | 16747.2 | 14949.2 | 29212.8 |
Common Stock | 414.899 | 415.44 | 415.895 | 278.451 | 278.846 |
Additional Paid-In Capital | 12461.4 | 12555.7 | 12668.7 | 12944.4 | 13020.5 |
Retained Earnings (Accumulated Deficit) | 19070.3 | 17926.7 | 4087.38 | 2435.23 | 16462.1 |
Unrealized Gain (Loss) | 93.701 | 533.078 | 400.958 | 37.067 | 287.199 |
Other Equity, Total | -860.86 | -450.393 | -355.848 | -333.099 | -378.576 |
Total Liabilities & Shareholders’ Equity | 64064.3 | 60543.3 | 47210.4 | 37514.2 | 49780.2 |
Total Common Shares Outstanding | 18468.1 | 18839.6 | 18861.5 | 18882.4 | 18910.1 |
Treasury Stock - Common | -1432.48 | -689.347 | -469.944 | -412.837 | -457.288 |
Capital Lease Obligations | 324.263 | 319.949 | 264.861 | 41.27 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total Current Assets | 26977.3 | 25934.9 | 25197.8 | 23503.2 | 23813.3 |
Cash and Short Term Investments | 15676.4 | 16921.7 | 15674.8 | 15224.6 | 10443.3 |
Cash | 2821.84 | 6413.98 | 4212.46 | 6213.97 | 5576.28 |
Cash & Equivalents | 472.126 | 2240.82 | 1852.99 | 3385.56 | 2452.05 |
Short Term Investments | 12382.4 | 8266.86 | 9609.39 | 5625.01 | 2415.02 |
Total Receivables, Net | 7188.86 | 5021.14 | 5354.76 | 4625.43 | 5174.74 |
Accounts Receivable - Trade, Net | 7108.97 | 4638.4 | 4947.84 | 4220.67 | 5059.33 |
Total Inventory | 2018.5 | 2328.84 | 2137.13 | 1937.74 | 1731.6 |
Prepaid Expenses | 2093.51 | 1663.26 | 2031.04 | 1715.45 | 6463.63 |
Total Assets | 65640.9 | 64064.3 | 64934.5 | 60543.3 | 56206.7 |
Property/Plant/Equipment, Total - Net | 9584.25 | 9251.18 | 8772.48 | 8516.06 | 8726.67 |
Goodwill, Net | 812.083 | 662.611 | 642.552 | 647.93 | 906.031 |
Intangibles, Net | 2129.61 | 1251.84 | 1214.07 | 1064.02 | 915.743 |
Long Term Investments | 24977 | 25950.3 | 28168.1 | 25875.1 | 17467.1 |
Other Long Term Assets, Total | 1160.69 | 1013.41 | 939.52 | 937.04 | 4377.86 |
Total Current Liabilities | 26865.4 | 20150.7 | 16265.5 | 15345 | 11485.5 |
Accounts Payable | 2137.21 | 1637.35 | 2676.47 | 1693.15 | 1620.73 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 10522.7 | 9723.84 | 4118.2 | 6585.04 | 1845.84 |
Other Current Liabilities, Total | 14205.5 | 8789.49 | 9470.83 | 7066.83 | 8018.92 |
Total Liabilities | 35651.6 | 34317.2 | 34720.3 | 30252.2 | 31631.1 |
Total Long Term Debt | 1031.34 | 4258.12 | 7983.31 | 5685.27 | 12258.7 |
Long Term Debt | 702.094 | 3933.86 | 7627.13 | 5365.32 | 11967.4 |
Capital Lease Obligations | 329.246 | 324.263 | 356.177 | 319.949 | 291.359 |
Deferred Income Tax | 623.447 | 831.791 | 1025.56 | 881.59 | 773.501 |
Minority Interest | 6469.51 | 8196.51 | 8530.46 | 7437.91 | 6533.45 |
Other Liabilities, Total | 661.88 | 880.146 | 915.477 | 902.433 | 579.924 |
Total Equity | 29989.3 | 29747 | 30214.2 | 30291.1 | 24575.6 |
Common Stock | 414.615 | 414.899 | 414.942 | 415.44 | 415.895 |
Retained Earnings (Accumulated Deficit) | 19372.6 | 19070.3 | 19267.9 | 17926.7 | 11801 |
Treasury Stock - Common | -1626.77 | -1432.48 | -1378.6 | -689.347 | -469.944 |
Total Liabilities & Shareholders’ Equity | 65640.9 | 64064.3 | 64934.5 | 60543.3 | 56206.7 |
Total Common Shares Outstanding | 18809.2 | 18468.1 | 18815.2 | 18839.6 | 18861.5 |
Additional Paid-In Capital | 12420.3 | 12461.4 | 12465.8 | 12555.7 | 12668.7 |
Unrealized Gain (Loss) | 59.346 | 93.701 | 271.418 | 533.078 | 517.148 |
Other Equity, Total | -650.759 | -860.86 | -827.306 | -450.393 | -357.207 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 5778.6 | 18572.7 | 5013.04 | 5583.82 | 11429.1 |
Cash From Operating Activities | 6265.15 | 5366.29 | 5325.34 | 5324.63 | 5094.36 |
Cash From Operating Activities | 906.16 | 881.414 | 846.661 | 634.649 | 426.151 |
Amortization | 101.686 | 89.917 | 763.491 | 898.351 | 727.113 |
Non-Cash Items | 642.081 | -12870.8 | -512.005 | -399.094 | -6875.88 |
Cash Taxes Paid | 892.085 | 726.716 | 959.176 | 1102.09 | 838.547 |
Cash Interest Paid | 339.524 | 179.623 | 215.307 | 339.602 | 153.264 |
Changes in Working Capital | -1163.38 | -1306.92 | -785.855 | -1393.09 | -612.103 |
Cash From Investing Activities | -4070.82 | -2515.98 | -7845.56 | -3824.34 | -616.1 |
Capital Expenditures | -1402.68 | -1741.06 | -1495.16 | -1481.14 | -1565.7 |
Other Investing Cash Flow Items, Total | -2668.14 | -774.915 | -6350.4 | -2343.2 | 949.599 |
Cash From Financing Activities | -3186.39 | -3225.26 | 2233.19 | 2800.84 | -2177.74 |
Financing Cash Flow Items | -2014.15 | -452.366 | -1724.7 | -1512.43 | -1167.66 |
Total Cash Dividends Paid | -1267.62 | -938.489 | -1187.02 | -819.688 | -710.328 |
Issuance (Retirement) of Debt, Net | 962.991 | -1501.48 | 5340.28 | 5165.01 | 304.665 |
Foreign Exchange Effects | 47.322 | -649.711 | 280.015 | 95.054 | 242.465 |
Net Change in Cash | -944.732 | -1024.66 | -7.016 | 4396.18 | 2542.99 |
Issuance (Retirement) of Stock, Net | -867.613 | -332.93 | -195.373 | -32.05 | -604.419 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Cash From Operating Activities | 6265.15 | 3948.94 | 5366.29 | 2335.55 | |
Changes in Working Capital | 6265.15 | 3948.94 | 5366.29 | 2335.55 | |
Cash From Investing Activities | -4070.82 | -5989.66 | -2515.98 | -4055.97 | |
Other Investing Cash Flow Items, Total | -2827.49 | -5362.69 | -2515.98 | -4055.97 | |
Cash From Financing Activities | -3186.39 | -1460.53 | -3225.26 | -761.689 | |
Financing Cash Flow Items | -3367.9 | -249.354 | -3225.26 | -761.689 | |
Foreign Exchange Effects | 47.322 | -32.85 | -649.711 | -113.766 | |
Net Change in Cash | -944.732 | -3534.09 | -1024.66 | -2595.87 | |
Capital Expenditures | -1243.32 | -626.972 | |||
Issuance (Retirement) of Stock, Net | -867.613 | -809.316 | |||
Issuance (Retirement) of Debt, Net | 1049.12 | -401.857 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Tse (Eric S Y) | Individual Investor | 21.5412 | 4050000000 | 0 | 2022-12-31 | |
France Investment China 1 Group Ltd | Corporation | 12.1229 | 2279254761 | 0 | 2023-06-30 | |
Tse (Ping) | Individual Investor | 8.8207 | 1658403124 | 27000000 | 2023-07-06 | LOW |
Cheng (Cheung Ling) | Individual Investor | 4.718 | 887034750 | 7000000 | 2023-04-04 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.6965 | 318957763 | -1764000 | 2023-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.0584 | 198993951 | -5565000 | 2023-09-30 | LOW |
First Sentier Investors (Hong Kong) Limited | Investment Advisor | 1.0019 | 188360500 | -3018000 | 2023-07-31 | LOW |
Tse (Hsin Stephen) | Individual Investor | 0.9268 | 174247000 | 0 | 2022-12-31 | |
Bosera Asset Management Co., Ltd. | Investment Advisor | 0.7277 | 136825000 | 48812000 | 2023-06-30 | MED |
State Street Global Advisors Asia Ltd. | Investment Advisor/Hedge Fund | 0.6734 | 126615223 | 4027416 | 2023-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.5832 | 109645878 | -17217700 | 2022-12-31 | LOW |
APG Asset Management N.V. | Pension Fund | 0.5599 | 105263158 | -13607922 | 2023-03-31 | LOW |
Hang Seng Investment Management Ltd. | Investment Advisor | 0.4592 | 86341681 | 8534944 | 2023-09-30 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.385 | 72390477 | 196000 | 2023-09-30 | LOW |
California Public Employees' Retirement System | Pension Fund | 0.3818 | 71777747 | -5538000 | 2022-06-30 | LOW |
HSBC Global Asset Management (Hong Kong) Limited | Investment Advisor | 0.3517 | 66124984 | 0 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.3506 | 65908990 | -5518500 | 2023-09-30 | LOW |
Schroder Investment Management (Hong Kong) Ltd. | Investment Advisor/Hedge Fund | 0.288 | 54143000 | 54143000 | 2023-07-31 | LOW |
China Asset Management Co., Ltd. | Investment Advisor | 0.2512 | 47229988 | 187088 | 2023-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.2365 | 44458499 | 0 | 2023-09-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sino Biopharmeceutical Company profile
Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.Industry: | Pharmaceuticals (NEC) |
湾仔港湾道1号会展广场辨公大楼41楼09室
HK
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com